Shandong Lukang Pharmaceutical Co., Ltd. (600789.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 7.53

From 52W high−32.87%

Volume20.22M

Market capCNY 7.52B

P/E (TTM)66.9x

P/S (TTM)1.4x

Div yield0.66%

Key dataSep 18, 2026

Open

CNY 7.53

From 52W high

−32.87%

Volume

20.22M

Market cap

CNY 7.52B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

13.1x

P/E (TTM)

66.9x

RSI (14)

51.2

MomentumView details →

1D Return

−1.91%

YTD Return

−16.15%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

66.9x

EV/EBITDA

13.1x

EV/Sales

1.4x

P/S (TTM)

1.4x

P/B (TTM)

1.5x

ProfitabilityView details →

Gross Margin

22.26%

Net Margin

1.52%

EBITDA Margin

10.69%

ROE (TTM)

1.68%

ROA (TTM)

0.88%

Asset Turnover

0.57x

GrowthView details →

Revenue YoY

−6.54%

EPS YoY

−80.13%

FCF YoY

+1900.12%

Revenue CAGR 3Y

+0.85%

EPS CAGR 3Y

−9.14%

EBITDA YoY

—

MomentumView details →

1D Return

−1.91%

YTD Return

−16.15%

1Y Return

−23.59%

RSI (14)

51.2

vs 50D SMA

+1.54%

vs 200D SMA

−8.35%

Capital & dividendView details →

Debt/Equity

0.40x

Current Ratio

1.53x

Quick Ratio

1.14x

Div Yield

0.66%

Div Rate

CNY 0.05

Div Growth 1Y

+1.82%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

5.71B

Net Income (TTM)

86.96M

Op. CF (TTM)

835.43M

Latest newsMore news →

Lukang Pharmaceutical's controlling subsidiary Shandong Lukang Pharmaceutical Group Saite Co., Ltd. received approval from the National Medical Products Administration to become the marketing authorization holder of Crisaborole Ointment, transferring the holder from Zhejiang Saimei Pharmaceutical Co., Ltd. to Saite.32d ago

Lukang Pharmaceutical received drug registration certificates from the National Medical Products Administration for dapagliflozin and metformin extended-release tablets (I) and (III), a combination product indicated for adults with type 2 diabetes.44d ago

Similar companies

汇宇制药-W688553.SH 上海谊众688091.SH 阳光诺和688621.SH 太极集团600129.SH 华北制药600812.SH SSY Group Limited02005.HK Find similar companies →

Latest newsMore news →

Lukang Pharmaceutical's controlling subsidiary Shandong Lukang Pharmaceutical Group Saite Co., Ltd. received approval from the National Medical Products Administration to become the marketing authorization holder of Crisaborole Ointment, transferring the holder from Zhejiang Saimei Pharmaceutical Co., Ltd. to Saite.32d ago Lukang Pharmaceutical received drug registration certificates from the National Medical Products Administration for dapagliflozin and metformin extended-release tablets (I) and (III), a combination product indicated for adults with type 2 diabetes.44d ago